Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

By Villegas A.   Arrizabalaga B.   Fernáández-Lago C.   Castro M.   Mayans J.R.   Gonzáález-Porras J.R.   Duarte R.F.   Remacha A.F.   Luñño E.   Gasquet J.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 951-960

Informa Healthcare

Access to resources Recommend Favorite

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 233-242

Karger

Access to resources Recommend Favorite

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload

By  

TRANSFUSION, Vol. 55, Iss. 7, 2015-07 ,pp. : 1613-1620

John Wiley & Sons Inc

Access to resources Recommend Favorite

Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 104-107

Karger

Access to resources Recommend Favorite